November 17, 2009 / 6:21 AM / 10 years ago

Novartis: lower H1N1 vaccine dose may suffice

ZURICH, Nov 17 (Reuters) - A U.S. clinical study suggests that just half a dose of the Novartis AG NOVN.VX H1N1 vaccine may be enough to generate a protective immune response, the Swiss drugmaker said on Tuesday.

Novartis said data from about 4,000 individuals suggested that half a dose of its U.S.-approved unadjuvanted H1N1 vaccine met immune criteria in adults and the elderly.

The data also showed that its adjuvant was well tolerated, which could potentially quadruple the Novartis vaccine supply. (Reporting by Emma Thomasson; Editing by Catherine Bosley)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below